Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here

被引：0
|
作者：
de Abreu, Tiago Tribolet [1 ]
机构：
[1] Hosp Espirito Santo Evora EPE, Serv Med, Evora, Portugal
来源：
HEART FAILURE REVIEWS | 2022年 / 27卷 / 06期
关键词：
Heart failure; Diastolic heart failure; Preserved ejection fraction; GUIDELINES; DIAGNOSIS; ECHOCARDIOGRAPHY; MANAGEMENT; COMMITTEE;
D O I：
10.1007/s10741-022-10244-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Heart failure with a preserved ejection fraction (HFpEF), previously known as diastolic heart failure, was first recognized more than 50 years ago. In spite of all the advances in the knowledge of HFpEF, important questions remain, namely the fact that no therapy has been shown to improve outcomes in these patients. The EMPEROR-Preserved Trial, a trial on the use of empagliflozin on patients with HFpEF, published in October 2021, was the first trial to ever show a change in outcomes in these patients. This article reviews the history of HFpEF and the problems related to its definition and diagnosis over time, and critically reviews the results of the EMPEROR-Preserved Trial in light of these.
引用
收藏
页码：2077 / 2082
页数：6
相关论文
共 50 条
  • [1] Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here
    Tiago Tribolet de Abreu
    Heart Failure Reviews, 2022, 27 : 2077 - 2082
  • [2] The Emperor-Preserved trial: what will change for patients with heart failure with preserved ejection fraction?
    Deaton, Christi
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2022, 21 (04) : 293 - 294
  • [3] Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos
    Shahzeb Khan, Muhammad
    Pedro Ferreira, Joao
    Bocchi, Edimar
    Bohm, Michael
    Pieter Brunner-La Rocca, Hans
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure, Eduardo
    Giannetti, Nadia
    Esteban Gomez-Mesa, Juan
    Janssens, Stefan
    Januzzi, James L.
    Gonzalez-Juanatey, Jose R.
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio, V
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Seronde, Marie-France
    Sim, David
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Tsutsui, Hiroyuki
    Verma, Subodh
    Vinereanu, Dragos
    Zhang, Jian
    Jamal, Waheed
    Schnaidt, Sven
    Schnee, Janet M.
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    Packer, Milton
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (12) : 2383 - 2392
  • [4] Uric Acid and Treatment With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial
    Doehner, Wolfram
    CIRCULATION, 2022, 146
  • [5] EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection Fraction and CKD
    Zannad, Faiez
    Kraus, Bettina J.
    Zeller, Cordula
    Pocock, Stuart
    Packer, Milton
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Anker, Stefan D.
    Butler, Javed
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : B3 - B3
  • [6] Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial
    Packer, Milton
    Butler, Javed
    Zannad, Faiez
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Carson, Peter
    Anand, Inder
    Doehner, Wolfram
    Haass, Markus
    Komajda, Michel
    Miller, Alan
    Pehrson, Steen
    Teerlink, John R.
    Schnaidt, Sven
    Zeller, Cordula
    Schnee, Janet M.
    Anker, Stefan D.
    CIRCULATION, 2021, 144 (16) : 1284 - 1294
  • [7] Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial
    Butler, Javed
    Siddiqi, Tariq Jamal
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Zannad, Faiez
    Anker, Stefan D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (02) : 245 - 248
  • [8] EMPAGLIFLOZIN IN HEART FAILURE WITH A PRESERVED EJECTION FRACTION ≥50%: RESULTS FROM THE EMPEROR-PRESERVED CLINICAL TRIAL
    Yousef, Zaheer
    HEART, 2022, 108 : A79 - A80
  • [9] Uric Acid and Treatment With Empagliflozin in Heart Failure with Preserved Ejection Fraction (HFpEF): the EMPEROR-Preserved Trial
    Green, Jennifer
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2023, 142 : S25 - S25
  • [10] Empagliflozin in Heart Failure With a Preserved Ejection Fraction ≥50% - Results From the EMPEROR-Preserved Clinical Trial
    Anker, Stefan D.
    CIRCULATION, 2021, 144 (25) : E571 - E572
12345